Use of data from multiple registries in studying biologic discontinuation: Challenges and opportunities

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.78, 2013, Pages

  Yoshida, Kazuki ^a,b   Radner, Helga ^a,c   Kavanaugh, Arthur ^d   Sung, Yoon Kyoung ^a,e   Bae, Sang Cheol ^e   Kishimoto, Mitsumasa ^f   Matsui, Kazuo ^b   Okada, Masato ^f   Tohma, Shigeto ^g   Weinblatt, Michael E ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b KAMEDA MEDICAL CENTER   (Japan)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^f ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^g SAGAMIHARA NATIONAL HOSPITAL   (Japan)

Author keywords

Anti rheumatic agents; Discontinuation; Remission; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; RITUXIMAB;

ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL PRACTICE; DAS28; DATA ANALYSIS; DISEASE CONTROL; DISEASE REGISTRY; DRUG COST; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HEALTH CARE FINANCING; HEALTH CARE SYSTEM; HUMAN; INFORMATION PROCESSING; LONGITUDINAL STUDY; MEDICAL LITERATURE; META ANALYSIS (TOPIC); METHODOLOGY; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH SUBJECT; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW;

EID: 84885797092     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. YOSHIDA K, SUNG Y-K, KAVANAUGH A et al.: Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis 2013.
2. NISHIMOTO N, AMANO K, HIRABAYASHI Y et al.: Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol 2013 May 3. [Epub ahead of print]
3. DROLET BC, JOHNSON KB: Categorizing the world of registries. J Biomed Inform 2008; 41: 1009-20.
4. GLIKLICH RE, DREYER NA eds. Registries for Evaluating Patient Outcomes: A User's Guide. 2nd ed. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010.
5. ELKAYAM O, PAVELKA K: Biologic registries in rheumatology: Lessons learned and expectations for the future. Autoimmunity Reviews 2012; 12: 329-36.
6. MOSES LE: The series of consecutive cases as a device for assessing outcomes of intervention. N Engl J Med 1984; 311: 705-10.
7. PINCUS T, STEIN CM: Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol 1997; 15 (Suppl. 17): S27-38.
8. PINCUS T: Limitations of randomized clinical trials in chronic diseases: explanations and recommendations. Adv Mind Body Med 2002; 18: 14-21.
9. KREMER JM, GIBOFSKY A, GREENBERG JD: The role of drug and disease registries in rheumatic disease epidemiology. Curr Opin Rheumatol 2008; 20: 123-30.
10. GRILLO E, VILLARD L, CLARKE A et al.: Rett networked database: an integrated clinical and genetic network of Rett syndrome databases. Hum Mutat 2012; 33: 1031-6.
11. LEON ME, BEANE FREEMAN LE, DOUWES J et al.: AGRICOH: a consortium of agricultural cohorts. Int J Environ Res Public Health 2011; 8: 1341-57.
12. CHATZIDIONYSIOU K, LIE E, NASONOV E et al.: Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 2012; 71: 374-7.
13. SILMAN A, SYMMONS D, SCOTT DGI, GRIFFITHS I: British Society for Rheumatology Biologics Register. Ann Rheum Dis 2003; 62 (Suppl. 2): ii28-29.
14. KREMER JM: The CORRONA database. Clin Exp Rheumatol 2005; 23: S172-7.
15. YAMANAKA H, TOHMA S: Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol 2006; 16: 75-6.
16. SUNG Y-K, CHO S-K, CHOI C-B et al.: Korean Observational Study Network for Arthritis (KORONA): establishment of a prospective multicenter cohort for rheumatoid arthritis in South Korea. Semin Arthritis Rheum 2012; 41: 745-51.
17. RAY WA: Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158: 915-20.
18. TAKEUCHI T, TATSUKI Y, NOGAMI Y et al.: Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 189-94. 19. TAKEUCHI T, HARIGAI M, INOKUMA S et al.:
19. TAKEUCHI T, HARIGAI M, INOKUMA S et al.: Postmarketing surveillance of tocilizumab for rheumatoid arthritis in japan interim analysis of 6424 patients. Ann Rheum Dis 2011; 70 (Suppl. 3): 610.
20. KOIKE T, HARIGAI M, INOKUMA S et al.: Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2011; 21: 343-51.
21. KOIKE T, HARIGAI M, ISHIGURO N et al.: Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 2012; 22: 498-508.
22. SOKKA T, KAUTIAINEN H, PINCUS T et al.: Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 2009; 68: 1666-72.
23. PUTRIK P, RAMIRO S, KVIEN TK et al.: Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2013.
24. KIM SC, YELIN E, TONNER C, SOLOMON DH: Changes in use of disease modifying antirheumatic drugs for rheumatoid Arthritis in the U.S. for the period 1983-2009. Arthritis Care Res (Hoboken) 2013.
25. ORLEWSKA E, ANCUTA I, ANIC B et al.: Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit 2011; 17: SR1-13.
26. LYMAN GH, KUDERER NM: The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol 2005; 5: 14.
27. FITZMAURICE GM, LAIRD WARE: Applied Longitudinal Analysis. Hoboken, NJ: Wiley; 2011.
28. KLEINBAUM DG, KLEIN M: Survival analysis. New York [etc.]: Springer; 2012.
29. FORTIER I, DOIRON D, BURTON P, RAINA P: Invited commentary: consolidating data harmonization-- how to obtain quality and applicability? Am J Epidemiol 2011; 174: 261-4; author reply 265-266.
30. IANNACCONE CK, LEE YC, CUI J et al.: Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford) 2011; 50: 40-6.
31. NISHIMOTO N, TAKAGI N: Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. Mod Rheumatol 2010; 20: 539-47. 32.
32. INOUE E, YAMANAKA H, HARA M, TOMATSU T, KAMATANI N: Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 2007; 66: 407-9.
33. LEE YC, CUI J, LU B et al.: Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. Arthritis Res Ther 2011; 13: R83.
34. ALETAHA D, MARTINEZ-AVILA J, KVIEN TK, SMOLEN JS: Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann Rheum Dis 2012; 71: 1190-6.